Objective To compare the risk of cardiovascular events between sodium glucose
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …

Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …

Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on
cardiovascular outcomes have not been well established. We pooled evidence from all …

Aims To determine the association between cardiovascular diseases (CVD) and SGLT2
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …

Background Cardiovascular outcome trials have shown cardiovascular benefit with sodium-
glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas …

The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular
(CV) outcomes in patients with type 2 diabetes mellitus has not been established. We aimed …

Background There have been scarce data comparing cardiovascular outcomes between
individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the …

Background The impact of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on
cardiovascular outcomes in patients with type II diabetes mellitus (DM) is not well …

Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …

Abstract Sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) have been shown to
mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 …